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THE EFFICACY OF 
SIMILASAN #2 EYEDROPS 
FOR THE RELIEF OF 
SIMPLE ALLERGIC CONJUNCTIVITIS 
Abstract 
Seasonal allergy sufferers have a wide choice of over the counter products to 
choose to alleviate their symptoms. Similasan #2 is a homeopathic over the 
counter product marketed to alleviate allergy symptoms. Homeopathy is the 
belief that "like cures like." Antigens, if taken in minute doses, will stimulate 
the bodies immune system. 
This double blind, matched group, clinical study compares the efficacy 
of Similasan #2, Visine AC, and sterile saline to alleviate various ocular signs 
and symptoms caused by seasonal allergies. Subjective and objective 
measurements were taken. 
The results showed that Visine AC, objectively, reduced conjunctival 
injection at a statistically significant level. Similasan #2 for allergies do 
demonstrate a reduction in allergic symptoms but not at any statistically 
significant levels. No other signs nor symptoms showed statistical 
significance. 
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INTRODUCTION 
Modern medicine is making remarkable strides in search of cures for existing 
medical conditions. Paralleling this growth is the resurgence of natural remedies. The 
public is becoming re-acquainted with treatment options not derived from synthetic 
chemical substances. An increasing patient population is turning back to a system of 
health-oriented medicine that stresses the maintenance of health and disease 
prevention. (Murray, 1991). Homeopathy is the study of medicine that treats a disease 
with a dilute, potentised agent, or drug, that will produce the same symptoms as the 
disease when given to a healthy individual. (Murray, 1991). Thus, products that are 
considered homeopathic often contain a plethora of plant, mineral and chemical 
substances. These medicines are used to treat a wide variety of human disease 
conditions. 
Seasonal allergies are a very common affliction within the general population. 
This study will concentrate on the ocular symptoms that are manifest with seasonal 
allergies and the degree to which they are alleviated employing a homeopathic 
medicine, "Similasan #2 for Allergies." 
"Anaphylaxis is an allergic response due to exposure to an antigen." (Busse, 
1976). There are vast chemical and environmental contaminants that can serve as 
antigens and produce such a response; drugs, foods, plants, pollen, animals, dust, and 
insect venom's to name only a few. Anaphylaxis occurs when the antigen stimulates the 
production of the IgE antibody, from which there are four types of hypersensitivity that 
results from an antigen. 
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Type I Hypersensitivity (Immediate or Anaphylactic) 
Type I reactions are triggered when an allergen attaches to two IgE molecules on 
a circulating basophil. The attachment results in a physical change of the cell thereby 
causing mast cell degranulation. Mast cells contain histamine, serotonin, heparin, 
neutral proteases, acid hydrolases and chemotactic factors responsible for the tissues' 
reaction to the antigen. Type I hypersensitivity reactions result from exposure to an 
allergen. This form represents the most common type of allergic response within 
ocular tissue. 
Type II Hypersensitivity 
Type II reactions result when an antibody attached to an intruding cell 
membrane. Cell lysis occurs as macrophages identify the antibody tagged cell and 
destroy the cell by phagocytose. Presently, there are no ocular diseases that are a result 
of this type of hypersensitivity. 
Type III Hypersensitivity 
Type III reactions require complement-mediated antibodies and may involve 
soluble or diffusible antigens. Intraocular inflammatory disease can be a result of type 
III reactions. (Allansmith, 1990). 
Type IV Hypersensitivity (Cell-mediated or Delayed reaction) 
Type IV reactions are due to a previous exposure to lymphokines and the 
interaction of primed T-lymphocytes and antigen. Approximately 24-48 hours after 
exposure to the antigen an allergic reaction will result. These are most commonly seen 
in drug allergies, graft rejections and poison ivy. (Allansmith, 1990). 
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Ocular Symptoms of Allergies 
There are many ocular signs and symptoms that manifest in response to an 
allergic reaction. Presentation may be unilateral or bilateral with itching as the primary 
presenting symptom. Visual acuity is generally stable and unaffected but can fluctuate, 
usually secondary to tearing. The bulbar conjunctival injection varies from pink to red. 
Both the palpebral and bulbar conjunctiva are chemotic, with chemosis varying from 
mild to severe. There is often a papillary response of the tarsal conjunctiva. Discharge 
is usually watery with mucous strands. There can be accompanying lid edema and 
hyperemia. (Disease classnotes, 1992). 
The primary allergies that affect ocular tissues are Type I and IV hypersensitivity. 
Type I reactions are frequently seasonal allergies associated with recurrent systemic 
allergic rhinitis. (Disease class notes, 1992). A person with Type I hypersensitivity is 
usually aware of their condition and frequently has a positive family history of allergies. 
The severity of the symptoms that present are dependent upon the individual's 
own immunological response to the allergen. All of the signs and symptoms listed 
above may not all be present in a mild case of ocular allergies. Therefore, since the 
degree of presentation is variable this will indicate the aggressiveness of treatment in 
order to alleviate the symptoms. 
TREATMENT 
Ocular allergies can present a wide spectrum of complications for the patient 
varying from a mild to a considerable threat to vision. (Bartlett, 1990). The primary 
concern in treatment is to identify and eliminate the allergen. 
However, identification of the allergen is not as easy as it sounds and other 
treatment options may need to be taken to alleviate the allergy symptoms. Non-
pharmacological based treatment options can include filtering methods to eliminate the 
allergen from the environment and to keep areas free of dust. The use of air 
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conditioning to regulate the humidity, thus, inhibiting the growth of dust mites and 
fungi may also be beneficial. (Bartlett, 1990). 
Itching, a primary feature of allergies, is often easily relieved using cold 
compresses. Soaking solutions are commonly used in conjunction with compresses. 
This method usually has a large safety margin. (Bartlett, 1990). This is the easiest 
symptom to alleviate but the drawback is that compresses only provides symptomatic 
rather than long term relief. Repeated applications may be necessary. (Bartlett, 1990). 
The solutions used, along with cold compresses, are listed below, and may be of further 
benefit for symptomatic relief. 
Active Ingredient 
Aluminum acetate 
(Burrow's solution) 
Table 1 
Potassium permanganate 0.1% 
Sodium chloride 
White vinegar 
Concentration 
(Aqueous Solution) 
1:40 to 1:20 
1:7 
3 Tbsp: 1 qt. water 
2 oz.: 1 qt. water (Bartlett, 1990). 
Vasoconstrictors are also employed in management of ocular allergies. Their 
mechanism of action is by binding to the alpha receptors on blood vessels stimulating 
the adrenergic agonists, leading to vasoconstriction of conjunctival blood vessels. 
(Disease classnotes, 1992). Phenylephrine, naphazoline, tetrahydrozoline, 
oxymetazoline and ephedrine are effective local vasoconstrictors when applied topically 
to the conjunctiva. All of these are available commercially except for ephedrine. 
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Table 2 
Ophthalmic decongestant preparations 
Generic Name 
Phenylephrine hydrochloride 
Naphazoline hydrochloride 
Oxymetazoline 
Tetrahydrozoline hydrochloride 
Trade Name 
Relief 
Prefrin Liquifilm 
Prefrin-Aa 
AK-Nefrin 
Isopto Frin 
Zincfrin 
Albalon Liquifilm 
Albalon-Aa 
Clear Eyes 
Degest2 
Naphcon-Aa 
Allerest Eye Drops 
Vasoclear 
Vasocon-Aa 
AK-Con Ophthalmic 
OcuClear 
Murine Plus 
Optigene3 
Soothe Eye Drops 
Vi sine 
aoecongestant/ antihistamine combination. 
Manufacturer 
Allergan 
Allergan 
All erg an 
Akorn 
Alcon 
Alcon 
Allergan 
Allergan 
Ross 
Barnes Hind 
Alcon 
Pharmacraft 
Iolab 
Iolab 
Akorn 
Schering 
Ross 
Pfeiffer 
Alcon 
Leeming 
Concentration 
(%) 
0.12 
0.12 
0.12 
0.12 
0.12 
0.12 
0.1 
0.05 
0.012 
0.012 
0.025 
0.012 
0.02 
0.05 
0.1 
0.025 
0.05 
0.05 
0.05 
0.05 
Published with permission from Jaanus SD, Pagano VT, Bartlett JD. Drugs affecting the autonomic 
nervous system. In: Bartlett JD, Jaanus SD, eds. Oinical ocular pharmacology, 2nd ed. Boston: 
Butterworth, 1989;69-148. 
However, side effects do result from constant use of ocular decongestants. 
Phenylephrine causes mydriasis which may precipitate an angle closure glaucoma 
attack. Rebound hyperemia may also occur with prolonged use. (Disease classnotes, 
1992). Xerosis and stinging are other side effects which may result from adrenergic 
agonists. 
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Antihistamines are often used to prevent the symptomatic effects of histamine. 
During the immune response, mast cells are activated and histamine is released. 
Histamine results in increased vascular permeability, intense itching, vasodilatation 
leading to the physiological changes associated with allergies. (Bartlett, 1990) 
Cromolyn sodium is a widely used ophthalmic preparation. Its action inhibits 
mast cell degranulation and proves to be very effective in treating those with allergic 
conjunctivitis. (Bartlett, 1990). Ocular symptoms are decreased with the use of 
cromolyn sodium and those patients using this preparation often require decreased use 
of antihistamines as well. 
There is another school of thought that takes us away from familiar modes of 
therapy and back to more traditional roles, that of naturopathy. "Naturopathic 
medicine has a belief in the ability of the body to heal itself if given the proper 
opportunity." (Murray, 1991). Vitalism is key to the naturopathic approach and regards 
symptoms presented are due to the patients' attempt to defend against the intruder 
rather than in response to the organism itself. (Murray, 1991). This mode of therapy 
includes changes in their dietary habits, nutritional supplements and botanical 
medicines. The botanical products used in the treatment of allergic conjunctivitis are 
listed below along with the suggested dosage. 
Botanical Medicine 
Ephedra sinica 
Glycyrrhiza glabra 
Scu ttelaria baicalensis 
Angelica sinensis 
Table 3 
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Dosage 
Crude herb or tea 0.5-1 gm 
Dried root or tea 1-2 gm 
Tincture(1 :5), 4-6ml 
Fluid extract(1:1), 0.5-2.0ml 
Powdered solid extract 
(4:1), 250-500 mg. 
(Murray, 1991). 
Ephedra(Ephedra sinica) has found to contain a physiologically active alkaloid 
that has been effective in the treatment of mild to moderate asthma and hay fever. 
(Murray, 1991). "If ephedra is used long term the effectiveness will diminish due to 
weakening of the adrenal glands due to the ephedrine. Hence, it may be necessary to 
use ephedra in combination with adrenal gland supportive herbs like Glycyrrhiza 
glabra and Panax ginseng along with Vitamin C, magnesium, zinc, vitamin B6 and 
pantothenic acid." (Murray, 1991). The ocular side effects that it may cause are 
mydriasis and contact lens staining. (Bert, 1992). 
Another medicinal plant used is Scutellaria baicalensis (Chinese Skullcap) and is 
said to contain anti-arthritic and anti-inflammatory effects. "Chinese skullcap does not 
appear to have any adverse effects at therapeutic levels ." (Murray, 1991). 
Angelica (Angelic sinensis) has proven to be very effective in the management of 
allergic symptoms and has long been used by Chinese herbalists. It inhibits the 
production of IgE antibodies which are elevated in those people with allergic 
complaints. (Murray, 1991). 
Liquorice (Glycyrrhiza glabra) is used extensively because it increases the half-
life of cortisol therefore increasing the anti-inflammatory action of cortisol in addition to 
decreasing some potential side effects of the hormone. (Murray, 1991). Liquorice 
contains properties similar to steroids therefore may cause cataracts, glaucoma, herpes 
simplex, keratitis, photophobia and retinal thrombosis. (Bert, 1992). 
There are other botanical products used in the management of asthma and 
allergic conditions; chili pepper (Capsicum frutescens), skunk cabbage (Symphlocarpus 
factida), green tea (Thea sinensis) and onions and garlic (Allium spp). Skunk cabbage 
contains volatile or aromatic oils and may produce the following ocular side effects; 
increased tearing, irritation, contamination of the contact lenses, and CNS effects. (Bert, 
1992). The botanical medicine to be used is dependent upon the symptoms presented, 
the action of the plant and prescribing the correct dosage level. 
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These are some of the more traditional and botanical remedies available in the 
treatment of ocular allergic conjunctivitis and in the management of allergic symptoms. 
Our thesis investigates the effectivity of a homeopathic eye drop, Similasan #2, to 
alleviate the ocular symptoms presented with seasonal allergies. The active ingredients 
used in Similasan #2 are Apis HPUS 6X 30.333%, Euphrasia HPUS 6X 30.333%, 
Sabadilla HPUS 6X 30.333%. Apis is a whole bee extract and provides relief in acute 
burning and edema of the eyelids. Euphrasia, also known as eyebright, fights against 
infections of the eyelid, the external eyelid, the conjunctiva and the tear ducts. 
Euphrasia is said to possess anti-catarrhal properties and may cause possible drying of 
the eye or decreased tearing. (Bert, 1992). Sabadilla is dried ripe seed of the Lily family. 
It provides relief for acute ocular irritation, sneezing, and runny nose. (Gaier, 1991 and 
Jouanny, 1984). These three medicinal agents are common homeopathic remedies given 
to alleviate allergic symptoms. (Jouanny, 1984 and Ullman,1988). 
METHODS 
Subjects 
The sample population is comprised of volunteers who were manifesting ocular 
symptoms of allergic conjunctivitis. The volunteers were placed into three categories 
depending on their initial subjective assessment of their allergic symptoms. The 
recruitment process employed the use of research announcements placed in several 
news media sources and local physicians' offices. For project participation the subjects 
were given a complimentary, comprehensive vision exam and a sample of the product 
they preferred upon completion of their trial. Subjects were rejected from the study if 
they were currently taking medication for their allergies which alleviated their ocular 
signs. There were 25 subjects of which 2 failed to complete the study because of failure 
to return after the five day trial period. 
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PROCEDURE 
A double blind matched group study was performed. Each subject was evaluated 
in three separate phases. The first examination was a preliminary assessment of the 
degree of severity of the objective and subjective ocular variables. The same examiner 
was used throughout the duration of the study. After the preliminary examination, the 
patient was put into one of three groups and then given an unmarked bottle of one of 
three products for a period of five days. The product was prescribed for use four times 
a day. As in the initial assessment, the patient was then re-examined immediately after 
the instillation of one drop in each eye, 0.5 hours and after five days. The categories 
under examination are listed in Table 4. The examiner used a Mentor biomicroscope 
and fluorescein strips for the completion of his evaluation. 
RESULTS 
Table 4 
Objective (examiner) 
Follicles I papillae 
TBUT 
Injection 
Chemosis 
Subjective (patient) 
Itching 
Burning 
Tearing 
Swelling 
Redness 
Runny nose 
Sneezing 
The Kruskal-Wallace one-way analysis of variance by ranks was used to 
determine if there was statistical significance between each of the three matched groups 
at the pre-trial, immediate, 0.5 hour, and 5 day trials. The Mann.;. Whitney U Test was 
then used to discern which group was significant and performed by comparing each 
group to the other at each significant trial period. 
At the start of the trials, there was no statistical significant difference between 
groups for the each of the signs and symptoms investigated, that is, the groups were 
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matched. The subjective findings were variable and showed no statistical significant 
differences between the three matched groups. The objective finding of conjunctival 
injection did show statistical significance (p < 0.05). Visine AC was shown to reduce 
injection at the immediate, 0.5 hour and 5 day trials as shown below: 
Group Trial p 
Visine AC vs Control Immediate 0.016 
Visine AC vs. Control 0.5 hour 0.003 
Visine AC vs. Control 5day 0.003 
Visine AC vs. Similasan #2 Immediate <0.02 
Visine AC vs. Similasan #2 0.5 hour <0.05 
No other objective findings showed any statistical significance. 
DISCUSSION 
Similasan #2 for allergies did provide subjective relief of swelling immediately 
upon instillation of the drop and up to 0.5 hours after, but, not at a statistically 
significant level. Similasan #2 did not prove to be as effective in long term relief of 
swelling as did Visine A.C. (Graph 1). All three products demonstrate a decrease in the 
relief of itching, however, Similasan #2 shows the most significant change. (Graph 2). 
Objectively, injection was relieved by all three products but Visine A. C. proved to be the 
most effective and Similasan #2 to be the least. (Graph 3). In the areas of TBUT, 
chemosis, papillae, tearing, sneezing, reduction of stinging, runny nose and burning, all 
products did not provide any significant relief. 
In any following studies to determine the efficacy of Similasan the wording 
should be changed to grade the effectiveness for the patient evaluation. The term 
"Degree of Relief" at the subjective post-instillation trials may have been difficult for 
subjects to interpret, thus confounding their assessment. During the initial patient 
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assessment, the subject was asked to the degree to which the symptoms were affecting 
them presently. Thus, the intrinsic difference between "degree of symptoms" and 
degree of relief'' negated any correlation in patient responses. 
A larger patient population is needed because relief is provided in the other 
categories examined. However, not enough to illustrate any significance, thus, a larger 
sample would be necessary to prove or to disprove any significant findings. 
At the completion of the evaluation, the volunteer was given a sample of 
Similasan #2 along with a complimentary vision exam. A randomized questioning of 
the volunteers were asked to determine if the homeopathic eye drop was effective in 
relieving their allergic signs. Again, the responses were conflicting, some found it to be 
an excellent product and some did not. 
It is under our recommendation that Similasan #2 is certainly a viable option for 
those peoples suffering from allergic symptoms but cannot be guaranteed as a "cure-all" 
for their symptoms. We have not found it to be detrimental by any means and does 
provide some degree of relief. We do not advise against its usage as treatment modality 
for ocular allergic conditions and will recommend its use to those people looking for 
alternative modes of treatment. 
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APPENDIX A 
PATIENT 
EVALUATION FORM-PRE 
NAME ___ _ 
DATE ___ _ 
TRIAL ___ _ 
The following criteria will be used to scale the degree which your 
allergic symptoms are affecting you. 
VERY 
ABSENT SLIGHT 
1 2 
BASELINE 
RED'JESS 
SWELLING 
ITCHING 
STINGING 
BURNING 
RUNNY NOSE 
SNEEZING 
TEARING 
SLIGHT MODERA1E 
3 4 
SEVERE 
5 
NAME ___ _ 
DATE ___ _ 
TRIAL ___ _ 
PATIENT 
POST-EVALUATION FORM-IMMED 
The following criteria will be used to scale the degree of relief the 
drops provided for you. 
NONE 
1 
REO'JESS 
SWELLING 
ITCHING 
STINGING 
BURNING 
RUNNY NOSE 
SNEEZING 
TEARING 
SLIGHT 
2 
RIGHT EYE 
IMMEDIATE 
MODERA1E 
3 
ClXD 
4 
EXCEllENT 
5 
LEFf EYE RIGHT EYE . LEFf EYE 
IMMEDIATE 0.5 HOURS 0.5 HOURS 
NAME ___ _ 
DATE ___ _ 
TRIAL ___ _ 
PATIENT 
POST-EVALUATION FORM-5 DAY 
The following criteria will be used to scale the degree of relief the 
drops provided for you. 
NONE 
1 
RED'JESS 
SWELLING 
ITCHING 
STINGING 
BURNING 
RUNNY NOSE 
SNEEZING 
TEARING 
SLIGHT 
2 
MODERA1E 
3 
RIGHT LEFf 
5 DAY- OD 5 DAY- OS 
CUD 
4 
EXCELLENT 
5 
CD 
BASELINE 
PAPILLA 
TBUT 
INJECTION 
CHEMOSIS 
TEAR PRISM 
Papilla 
1- absent 
2- slight 
3- moderate 
4- severe 
Tear prism 
measurement 
EXAMINER 
PRE-EVALUATION 
CB 
BASELINE 
TBUT- Time (sec) 
NAME ___ _ 
DATE ___ _ 
TRIAL ___ _ 
Injection/chemosis 
1-absent 
2-slight inj. s chemosis 
3-mod. inj. s chemosis 
4-mod. inj. c chemosis 
5-svre inj. c chemosis 
NAME ___ _ 
DATE ___ _ 
TRIAL ___ _ 
EXAMINER 
POST-EV ALUATION-IMMED 
CD 
IMMEDIATE 
PAPILLA 
TBUT 
INJECTION 
CHEWOSIS 
TEAR PRISM 
Papilla 
1- absent 
2- slight 
3- moderate 
4- severe 
Tear prism 
measurement 
cs CD cs 
IMMEDIATE 0.5 HOURS 0.5 HOURS 
TBUT- Time (sec) Injection/chemosis 
1-absent 
2-slight inj. s chemosis 
3-mod. inj. s chemosis 
4-mod. inj. c chemosis 
5-svre inj. c chemosis 
EXAMINER 
POST-EVALUATION-S DAY 
NAME ___ _ 
DATE ___ _ 
TRIAL ___ _ 
5 DAY- OD 5 DAY- OS 
PAPILLA 
TBUT 
INJECTION 
CHEtv10SIS 
TEAR PRISM 
Papilla 
1- absent 
2- slight 
3- moderate 
4- severe 
Tear prism 
measurement 
TBUT- Time (sec) Injection/chemosis 
1-absent 
2-slight inj. s chemosis 
3-mod. inj. s chemosis 
4-mod. inj. c chemosis 
5-svre inj. c chemosis 
APPENDIX B 
Patient's subjective data for burning 
BURNING TRIAL C VISINEA.C. 
NAME PRE-EVALUATION IMMEDIATE 0.5 HOURS 5DAYS 
1 1 1 1 4 
2 3 4 3 2 
3 3 1 1 1 
4 3 2 1 3 
5 3 2 1 2 
6 3 1 2 1 
7 4 1 1 1 
AVERAGE 2.86 1.71 1.43 2.00 
TRIAL B SALINE 
1 2 2 1 2 
2 4 3 2 1 
3 1 1 1 1 
4 2 1 1 2 
5 1 1 1 1 
6 4 5 4 2.5 
7 4 1 2 2 
AVERAGE 2.57 2.00 . 1. 71 1.64 
TRIAL A SIMILASAN#2 
1 1 1 1 1 
2 4 1 1 1 
3 1 1 1 1 
4 3 1 3 1 
5 4 4 5 3 
6 1 1 1 1 
7 2 2 2 2 
8 1 1 2 2 
9 1 1 1 3 
Average 2.00 1.44 1.89 1.67 
2.00 
1.80 
1 .60 
1 .40 
1.20 
~ 1.00 
(!) 
0.80 
0.60 
0.40 
0.20 
0.00 
PATIENT DEGREE OF RELIIEF FROM BURNING 
IMMEDIATE 0.5 HOURS 5DAYS 
• SIMILASAN#2 
D CCMRa. 
I) VISINE A.C. 
Patient's subjective data for itching 
ITCHING TRIALC VISINE A.C. 
NAME PRE-EVALUATION IMMEDIATE 0.5 HOURS I 5DAYS 
1 3 1 3 5 
2 I 4 4 2 I 2 
3 4 2 3 1 
4 2 1 1 4 
5 3 1 1 1.5 
-
6 1 1 1 1 
·-
7 5 I 2 2 1 
AVERAGE 3.14 1.71 1.86 2.21 
I 
TRIAL B SALINE 
1 3 1.5 1 2 
2 4 2 2 1 
3 4 2 2 2 
4 5 1 1 1 
5 2 1 1 3 
6 2 5 4 2.5 
7 4 1 .5 2 2 
AVERAGE 3.43 2.00 1.86 1 .93 
TRIAL A SIMILASAN#2 
1 1 1.5 1 1 
2 4 1 1 1 
3 5 4 4 4 
4 4 2 3 2 
5 4 3.5 3 2 
--
6 3 2 2 4.5 
7 2 3 3 3.5 
~-
8 2 1 2 2 
9 1 1 1 3 
Average 2.89 2.11 2.22 2.56 
PATIENT DEGREE OF RELIEF FROM IITCHING 
3.00 
2.50 
2.00 
1- I I _ SIMILASAN#2 
--
~ 
(I) 
~ 1.50 t• 
- -
- : 
- -
I D CCM"ROL 
II VISINE A.C. 
I I-
- - -
1 .00 
0.50 
0.00 
IMMEDIATE 0.5 HOURS 5DAYS 
Patient's subjective data for redness 
REDNESS TRIALC VISINEAC 
Subject PRE-EVALUATION IMMEDIATE 0.5 HOURS 5DAYS 
1 2 1 1 4 
2 4 4 4 4 
3 1 1 1 1 
4 3 2 2 2 
5 1 1 1 2 
--
6 2 1 1 1 
7 3 1 1 1 
AVERAGE 2.29 1.57 1.57 2.14 
TRIAL 8 SALINE 
1 1 1 1 1 
2 3 1 1 1 
3 3 1 1 1 
4 5 4 3 2 
5 3 2 2 1 
6 2 1 3 1 
7 4 1 1 2 
AVERAGE 3.00 1.57 1.71 1.29 
TRIAL A SIMILASAN#2 
1 2 1 .5 1 1.5 
2 4 1 1 1 
3 4 5 5 5 
4 4 2 4 2 
5 2 4 4 2 
6 1 1 1 1 
7 3 2 2 2 
8 1 1 2 2 
9 2 2 1.5 3 
Average 2.56 2.17 2.39 2.17 
PATIIENT DEGREE OF REU EF FROM REDNESS 
2.50 
2.00 
1.50 
• SIMI LASAN#2 
Cl) 
~ D CCNTROL 
CJ 
1.00 II VISINE A.C. 
0.50 
0.00 
IMMEDIATE 0.5 HOURS 5DAYS 
Patient's subjective data for runny nose 
RUNNY NOSE TRIAL C VISINEA.C. 
NAME PRE-EVALUATION IMMEDIATE 0.5 HOURS 5DAYS 
1 4 1 3 4 
2 3 1 1 1 
3 4 3 2 1 
4 4 1 1 1 
5 2 1 1 1 
6 2 1 1 2 
7 4 1 1 1 
AVERAGE 3.29 1.29 1.43 1.57 
TRIAL B SALINE 
1 3 1 1 1 
2 3 1 1 1 
3 2 1 1 1 
4 3 1 1 1 
5 4 3 3 1 
6 2 1 3 1 
7 2 1 1 1 
AVERAGE 2.71 1.29 1.57 1.00 
TRIAL A SIMILASAN#2 
1 1 1 1 1 
2 4 1 1 1 
3 5 2 2 3 
4 4 1 1 1 
5 4 1 2 1 
6 4 3 3 3 
7 4 4 1 4 
8 2 1 1 1 
9 1 1 1 1 
Average 3.22 1.67 1.44 1.78 
PATIENT DEGREE OF RELIEF FROM RUNNY NOSE 
2.00 
1.80 
1.60 
1.40 
1.20 
• SIMILASAN#2 
11.00 
(!) D CXMROL 
0.80 II VISINE A.C. 
0.60 
0.40 
0.20 
0.00 
IMMEDIATE 0.5HOURS 5DAYS 
Patient's subjective data for sneezing 
S1NEEZING TRIAL C VISlNE A.C. I 
NAM.E RE.:EVALUATlO ~MMED:IATE 0·.5 HOURS 50AYS 
1 4 1 2 4 
I 
2' 4 3 1 1 
3 3 2 1 1 
4 4 1 1 1 
5 1 1 , 1 
6 1i 1 1 1 
7 3 1 1 1 
AVERAGE 2.816 L43 1.14 1.43 
TRI.AL B SALrNE 
1 1 1 1 1 I 
2 3 1 1 1 
.3 3 1 1 1 
.4 4 1 1 1 
5 2 2 1 1 
16 1' 1 1 1 
7 2 1 1 1 
AVERAGE 2.29 1.1 4 1 .00 1.00 
TFUAL A , S:IM'JLASAN#2 
1 1 1 1 1 
2 2 1 1 1 
3 3 1 4 1 
4 4 1 1 1 
5 4 3 3 1 
I 6 4 1 1 3 
7 3 3 3 3 
8 3 1 1 1 
9 1 1 1 1 
Average 2. 78 1.44 1.78 1.44 
1.80 
1 .60 
1.40 
1.20 
i 1.00 
... 
" 0.80 
0.60 
0.40 
0.20 
0.00 
PATIENT DEGREE OF RELIEF FROM SNEEZING 
IMMEDIATE 0.5 HOURS 5DAYS 
SIMILASAN#2 
D CCNTRa. 
II VISINE A.C. 
Patient's subjective data for stinging 
STINGING TRIAL C VISINEA.C. 
NAME PRE-EVALUATION IMMEDIATE 0.5 HOURS .5 DAYS 
1 2 1 1 3 
2 2 3 3 2 
3 2 1 1 1 
4 2 2 2 2 
5 3 1.5 1 2 
6 3 1 2 1 
7 4 1.5 2 1 
AVERAGE 2.57 1.57 1. 71 1.71 
TRIAL B SALINE 
1 1 1 1 2 
2 4 2 1 1 
3 2 1 1 1 
4 2 1 1 1 
5 1 1 1 1 
6 3 5 4 2.5 
7 4 1.5 2 2 
AVERAGE 2.43 1.79 1.57 1.50 
TRIAL A SIMILASAN#2 
1 1 1 1 1 
2 4 1 1 1 
3 1 1 1 1 
4 3 1 3 1 
5 4 3 4 2 
6 2 2 2 1 
7 2 2 2 2 
8 1 1 2 2 
9 1 1 1 3 
Average 2.11 1.44 1.89 1.56 
2.00 
1.80 
1.60 
1.40 
1.20 
~ 1.00 
" 0.80 
0.60 
0.40 
0.20 
0.00 
PATIENT DEGREE OF RELIEF FROM STINGING 
IMMEDIATE 0.5 HOURS 5DAYS 
• SIMILASAN#2 
D CCNTROL 
lli1B VISINE A.C. 
Patient's subjective data for swelling 
SWELLING TRIALC I VISINE A.C. 
Subject PRE-EVALUATION IMMEDIATE 0.5 HOURS 5DAYS 
-
1 2 1 1 5 
--
2 2 4 4 4 
-
3 1 1 1 1 
4 2 1 2 2 
5 2 1 1 .5 2 
6 2 1 1 1 
7 3 1 1 1 
AVERAGE 2.00 1.43 1.64 2.29 
TRIAL 8 SALINE 
1 1 1 1 1 
2 2 1 1 1 
3 3 1 1 1 
4 4 2 1 1 
5 1 1 1 1 
6 2 1 2 1 
7 2 1 1 2 
AVERAGE 2.14 1 . 1 4 1.14 1.14 
TRIAL A SIMILASAN#2 
1 1 1 1 1 
2 4 1 1 1 
3 1 4 4 1 
4 2 1 1 1 
5 2 3 2 2 
6 1 1 1 1 
7 3 3 3 2 .5 
8 1 1 1 2 
9 1 1 1 1 
Average 1.78 1.78 1.67 1.39 
PATIENT DEGREE OF RELIEF FROM SWELLING 
2.50 
2.00 
1.501-
-
I • SIMILASAN#2 
Q) 
~ 100 111 D CO'JTFU Ill VISINE A.C . 
. 0.50 
0.00 
IMMEDIATE 0.5 HOURS 5DAYS 
Patient's subjective data for tearing 
TEARING TRIAL C VISINE A.C. 
NAME PRE-EVALUATION IMMEDIATE 0.5 HOURS 5DAYS 
1 1 1 1 5 
2 2 2 4 1 
3 3 2 2 1 
4 2 1.5 2 2 
5 3 2.5 1 3 
6 3 1 1 1 
7 4 1 1 1 
AVERAGE 2.57 1.57 1.71 2.00 
TRIAL 8 SALINE 
-
1 1 1 1 1 
2 2 1 1 1 
3 2 1 1 1 
4 3 1 1 2 
5 1 1 1 1 
6 2 1 1 1 
7 2 1 1 2 
AVERAGE 1.86 1.00 1.00 1.29 
TRIAL A SIMILASAN#2 
1 1 1.5 1 1 
2 4 1 1 1 
3 1 1 1 5 
4 3 2 3 2 
5 4 2 2 3 
6 3 1 1 1 
7 2 4 3 2.5 
8 1 1 1 1 
9 1 1 1 1 
Average 2.22 1.61 1 .56 1.94 
2.00 
1.80 
1.60 
1.40 
1.20 
Q) 
~ 1.00 
(!) 
0.80 
0.60 
0.40 
0.20 
0.00 
PATIENT DEGREE OF RELIEF FROM TEARING 
IMMEDIATE 0.5 HOURS SDAYS 
SIMILASAN#2 
D CCNTROL 
II VISINE A.C. 
APPENDIXC 
Examiner objective data for Similasan 
TRIAL A: Similasan 
PAPILLA PRE-EVALUATION IMMEDIATE 0.5HOURS 5DAY 
Subject 
1 2 2 2 2 
2 2 2 2 2 
3 2 2 2 0.5 
4 1.5 1.5 1.5 0.75 
5 2 2 2 2 
6 1 1 1 1 
7 2 2 2 1 
8 2 2 2 1 
9 1. 5 1.5 1.5 1 
average 1 .78 1.78 1.78 1.25 
TBUT 
1 9.5 1 0 1 0 8 
2 1 0 1 0 1 0 9 .5 
3 1 0 1 0 1 0 10 
4 1 0 1 0 8 1 0 
5 1 0 1 0 1 0 8 
6 1 0 1 0 1 0 9 
7 1 0 1 0 1 0 10 
8 1 0 1 0 1 0 7 .5 
9 1 0 1 0 1 0 10 
average 9.94 10.00 9.78 9.11 
INJECTION 
1 1 1 1 1.5 
2 0.5 0.5 0.5 1 
3 2 2.5 2.5 1 
4 2 2 2 1.75 
5 1 1 1 1 
6 1.75 1.75 1.25 1 
7 1 1 1 1.5 
8 1 1 1 1 
9 1.75 1.75 1.5 1.5 
average 1.33 1.39 1.31 1.25 
CHEMOSIS 
1 0 0 0 1 
2 0 0 0 0.5 
3 1 1 1 0 
4 1 1 1 1 
5 0 0 0 0 
6 1 1 1 1 
7 1 1 1 1 
8 1 1 1 1 
9 0 0 0 0 
average 0.56 0.56 0.56 0.61 
Examiner objective data for Control 
TRIAL B: Control 
PAPILLA PRE-EVALUATION IMMEDIATE 0.5HOURS 5 DAY 
Subject 
1 0.5 0.5 0.5 0 
2 0 0 0 2 
3 2 2 2 1 
4 2 2 2 0 .75 
5 2 2 2 2 
6 1 1 1 1 
7 1 1 1 1 
average 1 .21 1 .21 1 .21 1 . 11 
TBUT 
1 4 1 0 5 5.5 
2 3.5 3 .5 8 5 
3 1 0 1 0 1 0 1 0 
4 1 0 1 0 7 9 
5 9 1 0 1 0 10 
6 7.5 1 0 5.5 7.5 
7 1 0 1 0 1 0 1 0 
average 7. 71 9 .07 7 .93 8.14 
INJECTION 
--
1 1.25 1.25 1.25 1 
2 1.5 1.25 1.25 3 
3 2 2 2 2 
4 1.5 1 1 1.5 
5 1 1 1 1 .5 
6 1 1 1 1.5 
7 1.5 1 1 1.5 
average 1.39 1 .21 1.21 1. 71 
CHEMOSIS 
1 0.5 0.5 0.5 0.5 
2 0 0 0 1 
3 0 0 0 0 
4 1 1 1 1 
5 0 0 0 1 
6 1 1 1 0 
7 2 2 1 1 
average 0.64 0 .64 0.50 0.64 
Examiner objective data for Visine AC 
TRIAL C: Vlsine AC 
PAPILLA PRE-EVALUATION IMMEDIATE 0.5HOURS 5DAY 
Subject 
1 0 0 0 0 
2 2 2 2 1 
3 0 0 0 0 
4 1.5 1.5 1.5 0.5 
5 0 0 0 1 
6 0 0 0 0 
7 2 2 2 2 
average 0.79 0.79 0.79 0.64 
TBUT 
1 3 3 7 9 
2 1 0 1 0 1 0 1 0 
3 1 0 1 1 0 7 
4 1 0 1 0 9 1 0 
5 1 0 1 0 1 0 1 0 
6 1 0 1 0 1 0 1 0 
7 7 8 1 0 1 0 
average 8.57 7.43 9.43 9.43 
INJECTION 
1 1.5 0 0.5 1.5 
2 1 1 1 0.75 
3 1 1 1 1 
4 1 0 0 1 
5 1 0.5 0.5 1.5 
6 1 0.5 0.5 1 
7 1 0.5 0.5 0.5 
average 1.07 0.50 0.57 1.04 
CHEMOSIS 
1 1 1 1 0 
2 0 0 0 0 
3 0 0 1 0 
4 1 1 1 0 
5 0 0 0 1 
6 0 0 0.5 1 
7 0 1 1 1 
average 0 .29 0.43 0 . 64 0.43 
EXAMINER EVALUATON OF PAPILLA 
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1 .2 
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